

For the Period Ended March 31, 2021 Unaudited Quarterly Disclosure





Tower Health Overview


Tower Health ("Tower Health" or the "System") is a Pennsylvania nonprofit corporation that serves as the parent organization of seven acute care hospitals, an inpatient behavioral health facility, and related facilities that have formed an integrated healthcare system located in the Counties of Berks, Chester and Montgomery, Pennsylvania and the City of Philadelphia, Pennsylvania.

- Brandywine Hospital in Coatesville (171 licensed beds);
- Chestnut Hill Hospital in Philadelphia (148 licensed beds);
- Jennersville Hospital in West Grove (63 licensed beds);
- Phoenixville Hospital in Phoenixville (144 licensed beds*);
- Pottstown Hospital in Pottstown (232 licensed beds*);
- Reading Hospital, a teaching hospital in West Reading (737 licensed beds*, including 62 beds at a dedicated rehabilitation hospital); and
- St. Christopher's Hospital for Children, in partnership with Drexel University (188 licensed beds)
- On July 14, 2020, Tower Behavioral Health, a 144-bed inpatient facility and ambulatory campus opened under a joint venture with Acadia Healthcare.
- Tower Health Medical Group, a network of more than 128 primary care and specialty care practices, that includes 890 physicians and 411 Advanced Practice Providers.
- Tower Health Urgent Care Tower Health acquired 19 urgent care locations from Premier Urgent Care in 2018 and has added 6 new locations, making Tower Health the largest operator of urgent care centers in the metropolitan Philadelphia area according to the Philadelphia Business Journal
- Tower Health at Home, a regional home health and hospice organizations
- Tower Health Partners, a clinically integrated physician network with more than 3,100 providers
- Tower Health UPMC Health Plan, a joint venture with UPMC Health Plan that offers affordable health insurance coverage and access to high quality care in nine counties, with over 50,000 member lives in all lines of business including Medicare Advantage, Administrative Services Only (ASO) for self-insured employers, Individual (Exchange), as well as Commercial Group, Special Needs Plans (SNP), Managed Medical Assistance, and Children's Health Insurance Program (CHIP).
- Drexel University College of Medicine at Tower Health 120,000 square feet of new Medical School located ½ mile from Reading Hospital that will educate 200 enrolled medical students annually – starting July 2021
- Medical Education Expansion to 600-700 Residents and Fellows.

^{*}Number of licensed beds, excludes nursery




Tower Health at a Glance (excluding St. Christopher's)



- 1) 2020 Environics Analytics Estimate based on Tower Health combined PSA
- P) FY2020 market share based on Tower Health combined PSA
- 3) Excludes nursery beds and Observation; Includes 62 beds at Reading Hospital Rehabilitation at Wyomissing
- 4) Current as of June 30, 2020; includes THMG, THP, THUC, THAH, TowerDirect and all hospitals except St. Christopher's
- 5) Excludes normal newborns
- 6) Includes residents; 890 physicians and 411 APPs; source THMG as of June 30, 2020
- ncludes THMG, THP, THUC, THAH, Clinics, Foundation, and all hospitals except St. Christopher's
- 8) Actual THMG primary and specialty care visits
- 9) Includes 12,185 inpatient and 16,427 outpatient surgeries; Excludes endoscopies
- * All data is FY2020 unless otherwise noted

St. Christopher's Hospital for Children At-A-Glance (Dec 2019 - June 2020)



- (1) 2020 Environics Analytics Estimate
- (2) FY2020 PHC4 inpatient data; Patients age 0-17
- (3) Current as of June 30, 2020
- (4) Includes St. Christopher's Hospital for Children only
- (5) Includes 476 inpatient and 2,246 outpatient surgeries; Excludes endoscopies
- * All data is Dec 15, 2019-June 30, 2020 unless otherwise noted



Management Discussion and Analysis

YTD Consolidated Statement of Operations for the 9-Months Ended March 31, 2021 and 2020

(dollars in thousands)	Tower H	ealth	Obligated Group				
	9 Months end	ed Mar 31	9 Months end	ed Mar 31			
	FY21	FY20	FY21	FY20			
Unrestricted revenues and other support:							
Net patient revenue	1,489,862	1,510,776	1,120,535	1,237,542			
Other revenue	139,513	62,480	82,478	44,894			
Total revenues and other support	1,629,375	1,573,256	1,203,013	1,282,437			
Expenses:							
Salaries and benefits	1,000,927	940,242	557,883	605,945			
Supplies	258,251	242,950	221,758	220,722			
Interest	44,877	35,196	43,238	34,683			
Depreciation	79,354	72,888	74,128	68,012			
Total Purchased Services	249,937	215,825	150,301	146,140			
Repairs and maintenance	63,067	59,103	55,859	55,225			
Other	132,159	111,918	58,212	73,030			
Transaction related expenses	29,193	27,088	27,897	18,733			
Total expenses	1,857,765	1,705,208	1,189,276	1,222,491			
Income (loss) from operations	(228,390)	(131,952)	13,736	59,946			
Nonoperating gains:							
Investment income	71,214	(24,405)	71,190	(24,523)			
Other (losses) gains	(3,608)	9,875	(4,122)	(5,333)			
Nonoperating gains, net	67,606	(14,529)	67,069	(29,856)			
Excess of revenues, gains and other support							
over expenses Before Non-Controlling Interest	(160,784)	(146,482)	80,805	30,090			
Non-Controlling Interest	29,191	4,358					
Attributable to Tower Health and Subsidiaries	(131,593)	(142,124)	80,805	30,090			
Operating margin	-14.0%	-8.4%	1.1%	4.7%			
Operating cash flow*	(74,965)	3,219	158,999	181,374			
Operating cash flow margin**	-4.6%	0.2%	13.2%	14.1%			

^{*}Operating cash flow = Income (loss) from operations + interest + depreciation + transaction related expenses

Long-Term Debt Service Ratio for Tower Health Obligated Group for the nine months ended March 31, 2021 was 2.00x.

Note: \$50 million of CARES Act funds are included in revenue for the nine months ended March 31, 2021.

^{**}Operating cash flow margin = Operating cash flow / total revenues and other support



Management Discussion and Analysis (cont'd)

Subsequent Events Since March 31, 2021

THMG Restructuring

On May 10, 2021, Tower Health announced a restructuring of Tower Health Medical Group (THMG), our employed physician group. This action is expected to result in approximately \$30M in financial performance improvement by June 30, 2021, with another \$40M in improvements in FY 22. These changes are projected to impact up to 95 providers and 100 support staff.

As part of this system-wide reconfiguration of THMG, Tower Health will:

- 1. Consolidate practices to reduce expenses for office space leasing and equipment
- 2. Close some practice locations with consistently high net operating loss
- 3. Transition a number of providers from THMG employment to new agreements with other provider organizations or into independent practice.
- 4. Maintain an adjustment to physician and Advanced Practice Provider (APP) incentive compensation for the Fiscal Year 2021 and Calendar Year 2021 to align with what was implemented the previous year. Specifically, incentives will be paid at 60 percent of eligible dollars for all participants in these plans.

Operational Performance Quarter and 9-Months Ended March 31, 2021 vs March 31, 2020 and December 31, 2020

Tower Health ("Tower" or "System") operating performance for the quarter ended March 31, 2021 (Q3 FY2021) reflects a significant improvement over the quarter ended December 31, 2020 (Q2 2021). Operating income in Q3 FY2021 was negative \$70.4 million compared to Q2 FY2021 operating income of negative \$101.4 million. In Q3 FY2021, total revenue increased by 1.8% over Q2 FY2021, and the System generated a negative operating margin of 13.2% in Q3 FY 2021 in comparison to a Q2 FY2021 operating margin of negative 19.3%. Last quarter includes CARES Act grant funds received from the federal government. In Q3 FY2021 Tower received \$4.7 million for the Medical Group whereas no funds were received in Q2 FY2021. All CARES Act grant funds received were recognized and recorded in other operating revenue.

Nine months operating performance through March 31, 2021 compared to nine months through March 31, 2020 reflects a decline, particularly with the five Chester/Montgomery/Philadelphia ("CMP") hospitals. In the ninemonth period ended March 31, 2021, although total revenue increased by 0.37% compared with the nine-month period ended March 31, 2020, the System generated an operating margin of negative 15.6% in comparison to operating margin of negative 7.6%, respectively.

Nine months ended March 31, 2021 includes \$29.2million of one-time, non-recurring expenses. Of the \$29.2 million, there was an \$18 million Education grant provided to Drexel University and \$5.1 million was related to EPIC implementation costs at the Urgent Care and the St. Christopher Hospital for Children project, with the remainder related to other one-time transaction costs. Excluding the \$29.2 million in one-time, non-recurring expenses, the System's operating income in the nine month period ended March 31, 2021 was negative \$170.5 million, resulting in an operating margin of negative 10.8%, compared with negative 6.1% in the nine month period ended March 31, 2020.

*as defined on the prior pages



Management Discussion and Analysis (cont'd)

Excluding \$29.2 million in one-time, non-recurring expenses, the System's operating cash flow margin* for the nine-month period ended March 31, 2021 was negative 3.1%, compared with positive 0.7% in for the nine-month period ended March 31, 2020.

Across the system Tower has seen volumes decline due to multiple snowstorms in February, for Q3 2021 from Q2 FY 2021. Admissions are down 3.2%, ER inpatient visits are down 3.2% and outpatient ER visits are down 8.8%. Inpatient surgeries are down 5.2% while outpatient surgeries are down 4.0%. OP registrations are down 1.4%.

In the month of March volumes across the organization were either at or near a twelve-month high for Admissions, surgeries, OP registrations, Physician visits and Home Health visits. Total gross revenues were \$61.6 million over budget while OP revenues were \$35 million over budget versus the two previous months being \$53 million under budget. Operating EBIDA was \$10.6 million and Net operating income was negative \$3.1 million in March.

Reading Hospital continued to generate significant operating income. Reading Hospital produced \$98.3 million in operating income (12.13% op. margin) for the nine-month period ended March 31, 2021 compared with 13.4% in the nine-month period ended March 31, 2020. And Reading Hospital's operating cash flow margin* was 20.81%, compared with 20.89%, respectively.

Total revenue for the CMP hospitals for the nine months ending March 31, 2021 decreased 19.4% as compared with the prior year, while total expenses (including interest, depreciation, and amortization) decreased by 6.1%. The CMP hospitals' results declined in the nine month period ending March 31, 2021 as compared to the prior year, generating an operating income of negative \$113.8 million, for an operating margin of negative 29.1%, compared with the nine-month period ending March 31, 2020, which had an operating loss of \$52.6 million and an operating margin of negative 10.84%. The CMP hospitals generated operating cash flow* of negative \$61.8 million and operating cash flow margin* of negative 15.81% for the nine-month period ending March 31, 2021 compared to negative \$12.2 million and negative 2.5% for the nine month period ending March 31, 2020.

Guidehouse Recommendations

Guidehouse's assessment identified \$140 million in potential improvement to Operations and \$18 million in Cash Acceleration / Balance Sheet improvement opportunities, incremental to performance improvement initiatives already underway at Tower Health. The assessment opportunities were categorized into the following areas, with Revenue Cycle and the Physician Enterprise making up half of the improvement opportunity:

- Enterprise-wide Revenue Cycle
- Physician Services
- Pharmacy 340b
- Supply Chain
- System Laboratory
- Corporate Overhead
- Workforce Productivity

Since the end of the assessment, Tower Health and Guidehouse have developed a comprehensive set of solutions to begin rapidly implementing initiatives to improve the systems bond ratings and credit quality, while still supporting Tower's mission of providing safe and high quality care to its communities. Tower Health and Guidehouse have formed 'SWAT' implementation teams to rapidly implement opportunities identified from the assessment.

*as defined on the prior pages



Management Discussion and Analysis (cont'd)

As of the end of March 2021, Tower Health has implemented \$42M in realized Net Revenue and Cost Reduction initiatives. Realized improvements includes \$13.5M in one-time savings and \$28.9M in recurring benefits (estimated \$120M in recurring annualized benefit to the health system). Tower recently annualized restructuring plans for Tower Health Medical Group, which is an incremental benefit to Guidehouse's original assessment.

Strategic Process Lead by H2C

In April, Tower received multiple Indications of Interest in response to an RFP issued on behalf of Tower Health. These covered several permutations and combinations of transactions and assets. Tower's Board has authorized H2C to continue to pursue strategic options, which may result in more than one transaction. The Tower Board has set mid-July as our goal for completing the review of these Indications of Interest and working with the interested parties.

Impact of Changes in Accounting Methodologies on the Statement of Operations

As part of a mid-year review of our accounting procedures it was determined that in order to more accurately reflect the valuation of the accounts receivable, we changed our methodology to be more conservative. The methodology was changed in December 2020 to reflect this updated valuation, which resulted in a total adjustment for the six months ended December 31, 2020 of approximately \$25 million for Reading and the CMP hospitals.

Unrestricted Cash and Investments

Total balance sheet unrestricted cash and board-designated investment funds for capital improvements was \$729 million at March 31, 2021. This represents a decrease of \$35 million from December 31, 2020. Total days cash on hand for the System was 112 at March 31, 2021, representing a decrease of 4 days from December 31, 2020. Net assets were \$157 million at March 31, 2021. This represents a decrease of \$66 million from December 31, 2020.

Included in unrestricted cash and investments above is approximately \$166 million of CMS Advance Payments received during FY2020, which equates to approximately 25 days cash on hand. This amount is expected to start to be repaid using an amortized schedule beginning April 2021.

CARES Act Relief Funds

As of March 31, 2021, Tower Health has received a total \$148 million in grants from several phases of the CARES Act stimulus bill, which have been recognized as other operating revenue.

Tower Health System YTD Consolidating Income Statement w/CARES \$

								ŭ	ħ	Mar-21												
	Re	ading Hospital		Brandywine	C	Chestnut Hill		lennersville		Phoenixville		Pottstown		THMG		Parent		STC		Other		Consolidated
Inpatient Revenues	\$	1,481,810,271	\$	270,637,008	\$	458,589,264	\$	67,554,175	\$	353,577,410	\$	388,888,268	\$	_	\$		\$	445.625.395	\$		•	0.400.004.700
Outpatient Revenues		1,307,811,459	•	126,390,931	•	293,528,517	•	68,092,715	Ψ	333,648,271	Ψ	329,577,890	Ψ	603,539,495	Φ	-	Φ		Ф	-	\$	3,466,681,790
Total Revenues		2,789,621,729	_	397,027,939		752,117,781		135,646,891	_	687,225,681	_	718,466,157		603,539,495				642,093,438		51,516,603		3,756,199,319
Contractual Adjustments		1,952,753,716		327,163,896		653,141,849		101,287,031		567,492,084		592,837,235		413,833,055		-		1,087,718,833		51,516,603		7,222,881,109
Uncompensated Care		69,482,097		9,496,796		19,546,199		5,524,542		13,288,797		15,722,067		15,897,570		-		922,836,630 4,349,519		47,634,096		5,578,979,592
Net Revenue	\$	767,385,917	\$		\$	79,429,732	\$	28,835,318	-\$		\$	109,906,856	\$		\$		\$	160,532,685	\$	732,031 3,150,476	_	154,039,617
Interest Income		_	•	,,	•		•		۳	- 100,444,000	Ψ	100,000,000	Ψ	170,000,070	Ψ	-	Φ	100,552,665	Ф	3,150,476	Ф	1,489,861,900
Other Operating Income		58,580,566		1,419,039		12,607,802		2,932,230		10,238,510		763,135		12,751,495		1.045,805		20 200 202		050.070		-
Total Other Operating Revenues	-	58,580,566	_	1,419,039	_	12,607,802		2,932,230	_	10,238,510	_	763,135		12,751,495		1,045,805		38,320,393 38,320,393		853,972 853,972		139,512,947
Assets Released from Restriction		_		.,,		,,		2,002,200		10,200,010		700,100		12,731,433		1,045,605		30,320,393		653,972		139,512,947
Net Revenues		825,966,483		61,786,287		92,037,534	_	31,767,548	_	116,683,310		110,669,991		186,560,365		1,045,805		198,853,078	—	4,004,448		1,629,374,847
Expenses																		. ,				, ,
Salaries and Wages Benefits		232,988,161		28,296,044		36,247,177		13,035,033		38,758,595		38,189,929		238,100,675		-		111,116,937		99,842,222		836,574,772
		67,668,587		7,155,325		7,956,545		3,269,675		9,121,470		12,431,119		35,529,186		-		22,181,958		(13,696,448)		151,617,418
Contract Labor		8,588,530		2,051,527		207,850		115,313		436,653		896,833		56,446		-		69,897		312,018		12,735,068
Physician Fees		21,864,697		6,296,473		6,285,163		3,204,759		4,822,892		6,867,805		12,997,090		-		30,862,054		441,621		93,642,555
Professional Fees		3,856,353		1,512		14,003		-		3,447		-		13,997,590		250,898		11,828,163		23,345,485		53,297,451
Purchased Services		24,266,590		5,422,573		8,695,155		2,523,872		8,601,628		10,585,866		2,524,901		50,653		24,596,976		15,728,434		102,996,648
Billable Medical Supplies		39,682,785		5,224,641		4,993,040		2,182,583		14,141,148		11,635,300		1,130,282				8,462,074		306,582		87,758,435
Non Billable Medical Supplies		25,890,684		3,180,672		3,660,576		1,553,506		5,329,060		5,414,265		1,060,807				6,246,780		632,323		52,968,672
Other Supplies		6,919,423		27,130		988,119		484,333		850,920		530,966		1,033,294				734,347		1,455,182		13,023,714
Drugs		58,121,807		2,279,269		2,511,695		1,177,406		13,015,484		10,641,415		7,321,966		-		9,135,759		295,063		104,499,864
Repairs/Maintenance		11,752,210		3,288,817		2,951,178		1,284,026		3,277,651		4,076,964		473,408		-		5,714,581		30,247,785		63,066,620
Rental/Leases Utilities		3,860,392		1,305,693		961,934		408,510		4,030,339		1,423,444		13,221,544		-		8,495,589		8,144,996		41,852,443
		6,555,052		1,167,262		1,457,633		421,484		1,341,126		1,087,736		885,889		18,000		2,469,923		3,029,662		18,433,768
Taxes Licenses and Permits		2,470,343		258,377		277,134		10,228		254,587		38,619		346,272		-		337,785		341,861		4,335,207
Insurance Other Expenses		(2,277,004)		-		-		463		-		-		8,674,436		-		7,364,299		9,885,032		23,647,226
• ***		14,717,860		854,622		912,208		499,914		774,921		727,634		8,182,472		-		2,347,891		14,870,416		43,887,937
Corporate Allocation		86,516,241		11,787,560		14,428,596		4,772,890		18,112,412		19,452,242		11,640,709		9,339,608		-		(176,047,758)		2,500
Transaction and Integration Costs		27,897,076							_	-		_		251,271				1,044,515				29,192,862
Total Expenses		641,339,787		78,597,495		92,548,009		34,943,996		122,872,333		124,000,137		357,428,238		9,659,158		253,009,530		19,134,477		1,733,533,161
EBIDA		184,626,695		(16,811,209)		(510,475)		(3,176,448)		(6,189,023)		(13,330,147)		(170,867,873)		(8,613,354)		(54,156,452)		(15,130,029)		(104,158,314)
Interest Expense		22,506,030		5,681,794		8,713,810		777,305		1,882,254		8,570,097		(,,,		(0,010,004)		1,305,833		(4,559,636)		44,877,487
Depreciation		47,742,957		4,756,882		7,304,913		1,447,153		5,414,236		7,462,043		1,454,009		-		3,033,118		739,168		79,354,478
Operating Income/(Loss)		114,377,709		(27,249,884)		(16,529,198)		(5,400,906)		(13,485,514)		(29,362,286)		(172,321,882)		(8,613,354)		(58,495,403)		(11,309,561)		(228,390,279)
Contributions		87,497		_		9,500		_		(5,242)		150,806		90,321				23,838		209 740		005 400
Investment Income		46,254		_		-,		_		(0,2 12)		100,000		30,321		71,144,223		23,030		308,742		665,462
Other Non Oper (Income)/Expense		(4,089,397)		-		_		_		7,771		_				(282,808)		90,000		23,520		71,213,997
Total Income / (Loss) Before Non-				734.11							_					(202,000)		90,000		1,669		(4,272,765)
Controlling Interest	\$	110,422,063	\$	(27,249,884)	\$	(16,519,698)	\$	(5,400,906)	\$	(13,482,985)	\$	(29,211,480)	\$	(172,231,562)	\$	62,248,062	\$	(58,381,565)	\$	(10,975,630)	\$	(160,783,585)
Non-Controlling Interest															-			29,190,783			-	29,190,783
Attributable to Tower Health and Subsidiaries w/CARES Act \$	\$	110,422,063	\$	(27,249,884)	\$	(16,519,698)	\$	(5,400,906)	\$	(13,482,985)	\$	(29,211,480)	\$	(172,231,562)	\$	62,248,062	\$	(29,190,783)	\$	(10,975,630)	\$	(131,592,802)

Tower Health System Consolidating Balance Sheet Mar-21

						Mar-21							
	Reading	Hospital	CMP Hos	nitals		THMG		STC		Parent	Other		Consolidated
	recurring	riospitai	Oim 110.	pitais		111110		010		raicin	Other		Consolidated
Current Assets													
Cash & Cash Equivalents		1,891,466)	\$	31,465	\$	32,516	\$	17,079,474	\$	111,881,499	\$ 1,405,843	\$	118,539,331
Patient Accounts Receivable Net		3,306,928		726,382		23,398,674		31,759,610		-	7,616,525		239,808,118
Other Receivables		1,843,574		184,306		5,513,316		4,624,067		1,869,406	370,776		16,705,445
Affiliates Recv / (Payable)		5,179,903		285,855)		(171,749,259)		(4,340,564)		325,168,039	(83,558,598)		6,413,667
Estimated Third Party Receivables		5,917,161		394,409		-		15,064,131		-	-		37,375,701
Inventory of Supplies		1,749,841		95,472		-		4,957,254		-	27,449		77,730,017
Prepaid Expenses & Other Assets	2	6,325,342	11,	551,888		2,165,411		6,641,805		7,090,895	836,468		54,611,808
Self Insurance Fund Current		7,482,000		-		-		-		-	-		7,482,000
Bond Indenture Debt Service Current		-		-		-		-		6	-		6
Board Capital Improvements				-				-			 		-
Total Current Assets	44	9,913,282	(199,	101,932)		(140,639,342)		75,785,778	-	446,009,845	(73,301,537)		558,666,093
Assets Limited Use													
Self Insurance Fund	2	1,476,744		_		-		(1,762,021)		11,551,642	_		31,266,365
Swap Collateral Requirement		-		_		-		-			_		-
Regulatory Restricted Funds		-		_		_		2,000,000		2,000,000	-		4,000,000
Board Restricted		_		_		-		_,,		609,929,323	429,216		610,358,540
Total Assets Limited Use	2	1,476,744		-		-		237,979		623,480,965	 429,216		645,624,905
Property, Plant & Equipment Net	62	9,880,429	373.	989,305		14,633,771		8,982,529		35,995,607	60,693,882		1,124,175,522
			,							30,000,007			
Operating Lease Right of Use Asset	5	6,857,120	31,	79,843		25,293,286		99,117,752			 19,572,200		232,420,202
Other Assets													
Permanently Restricted Funds		-		-		-		-		-	21,129,883		21,129,883
Temporariliy Restricted Funds		-		-		-		-		_	25,048,335		25,048,335
Long Term Recv Affiliate		-		-		-		-		400,257,413	(400,257,413)		
Deferred Financing Costs		-		-		-		-			-		_
Deferred Compensation		325,739		-		-		-		-	-		325,739
Investments in Joint Ventures		53,655		-		-		-		3,358,065	1,062,477		4,474,196
Other Assets		8,010,372	130,4	158,131		233,043		51,132,288		26,417,512	27,668,126		243,919,471
Total Other Assets		8,389,765		158,131		233,043		51,132,288		430,032,989	 (325,348,591)		294,897,624
Total Assets	\$ 1,16	6,517,340	\$ 336,	925,347	\$	(100,479,243)	\$	235,256,325	\$	1,535,519,406	\$ (317,954,830)	\$	2,855,784,345
								Ver. 11.5 1.4440					
Current Liabilities													
Accounts Payable	\$ 7	1,164,762	\$ 36,	515,968	\$	10,683,557	\$	45 405 400			0.044.007	_	
Accrued Expenses		6,642,959		925,190	Ф	35,074,754	Ф	15,485,192 12,520,934	\$	40 540 405	\$ 2,611,207	\$	136,460,687
Accrued Vacation		4,351,634								18,518,195	2,107,502		106,789,534
Current Portion of Self Insurance Liability		9,916,021	11,	27,408		22,020,146		8,494,335		-	2,630,936		68,524,459
Operating Lease ROU Current Liability				-						-	(8,048)		9,907,973
Due to Third Parties		5,687,120		591,696		8,243,035		6,391,706		-	3,038,378		27,951,935
		8,664,678		134,762		-		1,767,377		-			14,866,816
Capital Lease Obligations - Short Term	_			345,455				936,796		-	(26,783)		2,755,468
Other Current Liabilities	7.	2,197,055	4,9	95,020		1,640,341		9,982,063			3,980,238		92,794,717
Current Portion Bonds Payable Affiliates				-		-		-		3,995,000	(3,995,000)		
Current Portion of Notes and Bonds Payable		3,995,000		-							 		3,995,000
Total Current Liabilities	22	2,619,228	75,3	335,500		77,661,833		55,578,402		22,513,195	10,338,431		464,046,589
Operating Lease Obligation LT	5	5,697,726	26 (988,147		17,050,251		92,726,046		_	16,533,822		208,995,992
Long Term Affiliate Payable		2,757,413	_0,	-		,550,251		75,000,000		-	(400,257,413)		37,500,000
Long Term Debt	-			_		_		70,000,000		1,293,717,814	(400,237,413)		1,293,717,814
Capital Lease Obligations - Long Term		(9,641)	16.5	43,816		(7,693)		1,260,438		1,200,717,014	(46,319)		17,740,601
Accrued Post Retirement Liabilities	27	1,568,656	10,			(1,000)		1,200,430		-	(40,319)		271,568,656
Self Insurance Liability		7,297,979		_				4,046,168		14,438,090	-		35,782,237
Gift Annuities		1,201,010						4,040,100		14,430,030	14,241		
Deferred Compensation Liability		830,472		369,240		47,211		-		-	53,267		14,241 1,300,190
Deferred Revenue	0	3,617,351		984,607		10,840,715		372,224		•	907,275		176,722,172
Asset Monetization	ŭ	0,011,001	, 0,	-		10,040,713		312,224		191,587,911	901,213		191,587,911
Total Liabilities	1,02	4,379,184	190.2	221,310		105,592,317		228,983,278		1,522,257,010	 (372,456,695)		2,698,976,403
										.,,	(,,		
Unrestricted Fund Balance	14	1,897,033	146,6	67,750		(206,071,560)		6,273,047		13,262,397	8,915,318		110,943,985
Temporarily Restricted		241,123		36,287		- 1		-		-	24,263,814		24,541,224
Permanently Restricted Donor Funds		-		-							 21,322,732		21,322,732
Total Net Assets	14	2,138,157	146,	704,036		(206,071,560)		-		13,262,397	 54,501,865		156,807,942
Net Assets W/O Donor Restrictions													
Total Health and Subsidiaries	14	1,897,033	146	67,750		(206,071,560)		3,136,523		13,262,397	8,915,318		107,807,462
Non-Controlling Interest	14	.,557,000	140,	,,,,,,		(200,071,000)		3,136,523		13,202,387	0,010,010		3,136,523
Net Assets W/ Donor Restrictions		241,123		36,287		_		J, 130,323		_	45,586,547		45,863,957
Total Net Assets	14	2,138,157	146	704,036		(206,071,560)		6,273,047		13,262,397	54,501,865		156,807,942
						(200,0, 1,000)		-,-,0,041		.0,202,007	04,001,000		100,001,042
Total Liabilities & Net Assets	\$ 1,16	6,517,340	\$ 336,	925,347	\$	(100,479,243)	\$	235,256,325	\$	1,535,519,406	\$ (317,954,830)	\$	2,855,784,345

Tower Health Consolidated Statement of Cash Flow For The Nine Month Period Ending March 31, 2021

Cash flows from operating activities and gains:		
Change in net assets		(151,985,000)
Adjustments to reconcile change in net assets to net		(131,303,000)
cash provided by operating activities and gains:		
Change in unrealized gain on investments		(66,471,000)
Change in fair value of interest rate swaps		(00,471,000)
Change in pension liability		(18,206,000)
Change in deferred revenue		4,032,000
Amortization of bond discount		387,000
Amortization of bond premium		(5,075,000)
Depreciation		79,354,000
Realized gains on investments		
Equity in (income) loss of affiliate		(12,774,000)
HHS Stimulus		14,310,000
Restricted contributions		(0.440.000)
Receivables from patients and others		(2,440,000)
Inventories		43,535,000
Prepaid expenses and other current assets		(11,657,000)
Deferred Compensation		(6,144,000)
Goodwill		(341,000)
Other assets		(119,000)
Long term debt		(6,014,000)
Third-party settlements		1,000
Accounts payable and other liabilities		(3,365,000)
Accrued vacation		23,296,000
Self-insurance cost		1,739,000
Och madrance cost		4,311,000
Net cash provided (used) by operating activities and gains	\$	(113,626,000)
Net cash provided (used) by operating activities and gains	\$	(113,626,000)
Cash flows from investing activities:	\$	(113,626,000)
Cash flows from investing activities: Acquisition of property, plant and equipment	\$	
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase	\$	(113,626,000) (54,528,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees	\$	(54,528,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees	\$	(54,528,000) - 1,101,000
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited	\$	(54,528,000) - 1,101,000 (362,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees	\$	(54,528,000) - 1,101,000 (362,000) 34,835,000
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited	\$	(54,528,000) - 1,101,000 (362,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited	\$	(54,528,000) - 1,101,000 (362,000) 34,835,000
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities	:	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities:	:	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities: Restricted contributions and investment income received	:	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000) 2,440,000
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities: Restricted contributions and investment income received Finance Lease Issuance	:	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities: Restricted contributions and investment income received Finance Lease Issuance Payments of long-term debt (including current portion)	:	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000) 2,440,000
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities: Restricted contributions and investment income received Finance Lease Issuance Payments of long-term debt (including current portion) Proceeds from line of credit	:	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000) 2,440,000 2,604,000
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities: Restricted contributions and investment income received Finance Lease Issuance Payments of long-term debt (including current portion) Proceeds from line of credit Repayments of line of credit	:	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000) 2,440,000 2,604,000 (3,750,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities: Restricted contributions and investment income received Finance Lease Issuance Payments of long-term debt (including current portion) Proceeds from line of credit	:	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000) 2,440,000 2,604,000 (3,750,000) 7,500,000
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities: Restricted contributions and investment income received Finance Lease Issuance Payments of long-term debt (including current portion) Proceeds from line of credit Repayments of line of credit Payments of finance leases	\$	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000) 2,440,000 2,604,000 (3,750,000) 7,500,000 (62,500,000) (1,489,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities: Restricted contributions and investment income received Finance Lease Issuance Payments of long-term debt (including current portion) Proceeds from line of credit Repayments of line of credit	:	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000) 2,440,000 2,604,000 (3,750,000) 7,500,000 (62,500,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities: Restricted contributions and investment income received Finance Lease Issuance Payments of long-term debt (including current portion) Proceeds from line of credit Repayments of line of credit Repayments of finance leases Net cash provided (used) in financing activities	\$	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000) 2,440,000 2,604,000 (3,750,000) 7,500,000 (62,500,000) (1,489,000) (55,195,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities: Restricted contributions and investment income received Finance Lease Issuance Payments of long-term debt (including current portion) Proceeds from line of credit Repayments of line of credit Payments of finance leases Net cash provided (used) in financing activities Net change in cash and cash equivalents	\$	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000) 2,440,000 2,604,000 (3,750,000) 7,500,000 (62,500,000) (1,489,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities: Restricted contributions and investment income received Finance Lease Issuance Payments of long-term debt (including current portion) Proceeds from line of credit Repayments of line of credit Payments of finance leases Net cash provided (used) in financing activities Net change in cash and cash equivalents	\$	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000) 2,440,000 2,604,000 (3,750,000) 7,500,000 (62,500,000) (1,489,000) (55,195,000)
Cash flows from investing activities: Acquisition of property, plant and equipment Contribution restricted for capital purchase Distribution to/from equity investees Investment in equity investees Sales from assets whose use is limited Purchases from assets whose use is limited Net cash provided (used) by investing activities Cash flows from financing activities: Restricted contributions and investment income received Finance Lease Issuance Payments of long-term debt (including current portion) Proceeds from line of credit Repayments of line of credit Repayments of finance leases Net cash provided (used) in financing activities	\$ \$	(54,528,000) - 1,101,000 (362,000) 34,835,000 (50,578,000) (69,532,000) 2,440,000 2,604,000 (3,750,000) 7,500,000 (62,500,000) (1,489,000) (55,195,000) (238,353,000)

TOWER HEALTH AND SUBSIDIARIES

Consolidated Statement of Changes in Net Assets

Period Ending March 31, 2021

(Dollars in thousands)

	2
Changes in net assets:	
Deficiency of revenues, gains, and other	
support over expenses (160,794) - (160,794	4)
Net change in unrealized gains (losses) on investments (139) 1,667 1,528	3
Net change in realized gains on investments - 2,459 2,459	9
Change in pension liability	
Restricted contributions - 2,440 2,440)
Net assets released from restrictions (646) (850) (1,496	3)
Change in beneficial interest in trusts - 3,215 3,215	5
Non-Controlling Interest	
Other (92) 755 663	3
Change in net assets(161,671)9,686(151,988	<u>5)</u>
Net assets at March 31, 2021 \$ 45,864 156,807	<u>7_</u>

Tower Health Historical Utilization of Services For the Years Ended 2019 through 2021 YTD

Year to Date March 31, 2021

real to Date March 31, 2021			
	2019	2020	FY2021 YTD Consolidated
Beds in Service:			Consonantea
Adults & Critical Care	1,109	1,010	991
Obstetrics/Gynecology	60	91	72
NICU	30	34	34
Pediatrics	19	19	19
Skilled Nursing	50	50	50
Acute Rehab	76	76	73
Observation	-	, ,	29
Psych	152	152	103
Subtotal	1,496	1,432	1,371
Newborn	73	73	52
Total	1,569	1,505	1,423
Admissions:			
Medical/Surgical	51,879	51,939	39,783
Obstetrics/Gynecology	4,910	4,993	3,443
NICU	417	282	180
Pediatrics	1,368	1,379	895
Skilled Nursing	1,197	1,075	906
Acute Rehab	1,548	1,554	1,149
Psych	3,652	2,867	1,600
Subtotal	64,971	64,089	47,956
Newborn	4,200	4,319	2,935
Total	69,171	68,408	50,891
Potiont Dove			
Patient Days: Medical/Surgical	224 775	222 151	105.041
Obstetrics/Gynecology	224,775 12,875	233,151 12,696	195,041 8,591
NICU	9,111	8,889	5,910
Pediatrics	2,569	2,578	1,723
Skilled Nursing	16,711	16,917	13,662
Acute Rehab	20,931		
Psych	42,582	22,021 32,366	18,226
Subtotal _	329,554	328,618	21,602
Newborn			264,755
Total -	8,752 338,306	8,710	5,668
Total	338,300	337,328	270,423
Acuity:			
Case Mix Index	1.43	1.43	1.49
*Prior to FY20, the CMP Hospitals did not segregate beds as Medical/Surgical includes Adult and Critical Care	mong Med/Surg, OBGYN and NI	CU, updated in FY20.	
Length of Stay:	4.00	4.40	100
Medical/Surgical	4.33	4.49	4.90
Obstetrics/Gynecology NICU	2.62	2.54	2.50
	21.85	31.52	32.83
Pediatrics	1.88	1.87	1.93
Skilled Nursing Acute Rehab	13.96 13.52	15.74	15.08
		14.17	15.86
Psych	11.66	11.29	13.50
Total Newborn	5.07 2.08	5.13 2.02	5.52 1.93
Occupancy Rates:			
Medical/Surgical	55.5%	63.1%	71.8%
Obstetrics/Gynecology	58.8%	38.1%	43.5%
NICU	83.2%	71.4%	63.4%
Pediatrics	37.0%	37.1%	33.1%
Skilled Nursing	91.6%	92.4%	99.7%
Acute Rehab	75.5%	79.2%	91.1%
Psych	76.8%	58.2%	76.5%
Total	60.4%	62.7%	70.5%
Newborn	32.8%	32.6%	39.8%

Tower Health Historical Utilization of Services

Year to Date March 31, 2021	2019	2020	FY2021 YTD Consolidated
Surgeries:			as of 03/31/21
IP	14,306	12,616	9,790
OP	23,595	18,542	16,979
Total	37,901	31,158	26,769
Emergency Visits:			
IP	48,736	50,602	38,995
OP	229,031	236,667	145,920
Total	277,767	287,269	184,915
OP Registrations	1,304,467	1,388,777	471,028
Physician Vists:	1,728,810	1,871,449	1,953,251
Urgent Care Visits	108,072	159,947	178,476
Telehealth	N/A	16,757	70,452
		June only	

Year to Date March 31, 2021

		Admiss	ions		Q2 FY2021 vs
	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q3 FY2021
Reading	7,828	9,500	9,462	9,017	
Brandywine	1,240	1,403	1,393	1,385	
Chestnut Hill	1,498	1,645	1,850	1,778	
Jennersville	514	593	669	564	
Phoenixville	1,612	1,756	1,899	1,923	
Pottstown	1,793	2,018	2,007	1,982	
St Chrisopher's	682	974	971	1,014	
Total	15,167	17,889	18,251	17,663	-3.2%
		IP Sui	rg		
	Q4 2020	Q1 2021	Q2 2021	Q3 2021	
Reading	1,281	1,837	1,735	1,635	
Brandywine	154	179	160	164	
Chestnut Hill	204	331	288	299	
Jennersville Phoenixville	110	133	140	96	
Pottstown	244 257	301 376	298 373	311	
St Chrisopher's	187	319	247	337 232	
Total	2,437	3,476	3,241	3,074	-5.2%
		OB S.			
	Q4 2020	OP Su <u>Q1 2021</u>	rg <u>Q2 2021</u>	Q3 2021	
Reading	846	1,477	1,491	1,408	
Brandywine	183	293	290	259	
Chestnut Hill	216	363	369	445	
Jennersville	230	350	359	327	
Phoenixville	618	1,278	1,323	1,223	
Pottstown	340	654	851	761	
St Chrisopher's	702	1,122	1,156	1,180	
Total	3,135	5,537	5,839	5,603	-4.0%
		IP ER			
Dandina	Q4 2020	Q1 2021	Q2 2021	Q3 2021	
Reading Brandywine	5,024	6,002	6,239	6,108	
Chestnut Hill	1,080 1,404	1,198 1,421	1,220	1,160	
Jennersville	498	553	1,701 627	1,610 543	
Phoenixville	1,062	1,098	1,200	1,191	
Pottstown	1,491	1,721	1,834	1,824	
St Chrisopher's	409	565	610	570	
Total	10,559	12,558	13,431	13,006	-3.2%
		OP EF	2		
	Q4 2020	Q1 2021	Q2 2021	Q3 2021	
Reading	14,294	19,543	16,780	16,122	
Brandywine	3,373	4,351	4,119	3,700	
Chestnut Hill	5,112	6,845	7,500	6,373	
Jennersville	2,241	2,741	2,487	2,292	
Phoenixville	2,646	3,811	4,174	3,565	
Pottstown	4,659	6,218	6,115	5,732	
St Chrisopher's	5,106	7,929	8,228	7,295	
Total	37,431	51,438	49,403	45,079	-8.8%
		OP Registra	ations		
	Q4 2020	Q1 2021	Q2 2021	Q3 2021	
Reading	54,027	82,004	83,154	82,838	
Brandywine	6,041	9,091	9,014	8,913	
Chestnut Hill	6,059	13,506	15,240	14,786	
Jennersville	3,224	5,844	6,028	6,058	
Phoenixville					
	8,768	16,149	16,672	16,292	
Pottstown	9,295	15,189	15,149	14,691	
				•	-1.4%

TOWER HEALTH NET REVENUE BY PAYOR CATEGORY

Reading & CMP Hospitals (Excluding St. Chris)	3Q - March <u>FY 2021</u>	March- YTD FY 2021	Annual FY2020	Annual FY2019
Category			<u> </u>	112013
Medicare Including Mgd MCR	37%	35%	34%	30%
Medicaid Including Mgd MCD	10%	10%	15%	
Blue Cross	27%	28%		12%
Non-Blue Commercial			26%	33%
	21%	22%	18%	19%
Other & Self Pay	5%	5%	7%	6%
Total	100%	100%	100%	100%
* Decidion of Contract				10078

^{*} Reading and CMP Hospitals only Excluding St. Christopher's